NDC 17856-0353-2 - Pharbetol Regular strength
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 17856-0353
- Requested NDC
- 17856-0353-2
- Package NDCs from labels
- 17856-0353-2, 17856-0353-1, 17856-0353-4, 17856-0353-3
- Manufacturer
- ATLANTIC BIOLOGICALS CORP.
- Effective date
- 2025-06-05
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| PHARBEST IBUPROFEN Drug Facts | ATLANTIC BIOLOGICALS CORP. | 2025-06-05 | HUMAN OTC DRUG LABEL |
| Pharbetol Regular strength - ATLANTIC BIOLOGICALS CORP. | UNIT DOSE SOLUTIONS | ATLANTIC BIOLOGICALS CORP. | UNIT DOSE SOLUTIONS | 2024-04-30 | HUMAN OTC DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 17856-0353-1 | 2024-06-26 | C162847 | 48780-1 | 1030e365-250f-111a-e063-dadaa90a10e2 | PHARBEST IBUPROFEN Drug Facts |
| 17856-0353-1 | 2024-01-30 | C162847 | 48780-1 | 1030e365-250f-111a-e063-dadaa90a10e2 | PHARBEST IBUPROFEN Drug Facts |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 17856-0353-1 | PharbetolRegular strength | 100 in 1 BOX, UNIT-DOSE | TABLET | 100 | 3 | |
| 17856-0353-2 | PharbetolRegular strength | 1 in 1 POUCH | TABLET | 1 | 3 | |
| 17856-0353-4 | PharbetolRegular strength | 24 in 1 BOTTLE | TABLET | 24 | 3 | |
| 17856-0353-3 | PharbetolRegular strength | 28 in 1 BOTTLE | TABLET | 28 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 17856-0353 | PHARBETOL REGULAR STRENGTH (ACETAMINOPHEN) TABLET [ATLANTIC BIOLOGICALS CORP.] | 2 | Current NDC, Legacy NDC, 3 package rows | 20240627_05a91d24-b498-4ba2-a275-68b871cf62d2.zip |
| 17856-0353 | PHARBETOL REGULAR STRENGTH (ACETAMINOPHEN) TABLET [ATLANTIC BIOLOGICALS CORP.] | 1 | Current NDC, Legacy NDC, 1 package rows | 20240508_bd26081c-e81e-42e8-b3da-2813863a51df.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Tukol Honey Daytime Cold and Flu | ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE HYDROCHLORIDE | Genomma Lab USA | c9572b16-8e28-4f98-bd87-8a07721a49c6 | 2024-10-21 | Warnings | 362O9ITL9D |
| Pain Relief Extra Strength | ACETAMINOPHEN | HEB | f17a18b0-a7c2-4c64-868c-460cf34e1f7d | 2024-10-21 | Warnings | M013 362O9ITL9D |
| Tukol Honey Nighttime Cold and Flu | ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND DOXYLAMINE SUCCINATE | Genomma Lab USA | bf25f38e-3549-4f78-be90-46605b5f2c11 | 2024-10-21 | Warnings | 362O9ITL9D |
| Pain Relief Extra Strength | ACETAMINOPHEN | HEB | 0863aeaa-15ec-4c67-ba79-4dad54555bd2 | 2024-10-21 | Warnings | M013 362O9ITL9D |
| Allergy Multi Symptom | ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, AND PHENYLEPHRINE HYDROCHLORIDE | HEB | a6cdc084-c23b-e733-e053-2995a90a3506 | 2024-10-21 | Warnings | 362O9ITL9D |
| Acetaminophen | ACETAMINOPHEN | American Health Packaging | 3c0175a0-175b-48b8-9192-3f869690c0f2 | 2024-10-21 | Warnings | M013 362O9ITL9D |
| Acetaminophen | ACETAMINOPHEN | American Health Packaging | 0d6553bd-3e18-4624-a83a-899bcafb3272 | 2024-10-21 | Warnings | M013 362O9ITL9D |
| Childrens Acetaminophen Oral Suspension | ACETAMINOPHEN | American Health Packaging | 8231dd91-e9e6-4350-a485-fa95d65a6d25 | 2024-10-21 | Warnings | M013 362O9ITL9D |
| Cold Flu Severe | ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | HEB | ea39a67d-8a99-4f7c-9925-94b07d0b1092 | 2024-10-21 | Warnings | 362O9ITL9D |
| Head Congestion plus Flu Severe | ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | HEB | eb7920a3-3c25-6aa1-e053-2995a90ac2b9 | 2024-10-21 | Warnings | 362O9ITL9D |
| Mucus Relief Sinus Severe Congestion Relief | ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | HEB | 9cbb3ab1-5f32-421e-9f28-d99be9447e9f | 2024-10-21 | Warnings | 362O9ITL9D |
| Head Congestion plus Mucus PE | ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | HEB | eb791902-e2c3-5662-e053-2995a90a37fd | 2024-10-21 | Warnings | 362O9ITL9D |
| Cold Head Congestion Severe | ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | HEB | c3849b66-697f-4f6e-93ab-76de031b3c70 | 2024-10-21 | Warnings | 362O9ITL9D |
| DAYTIME SEVERE COLD AND FLU MAXIMUM STRENGTH | ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | HEB | 774e8bee-1ab5-4587-82e4-31da8ec83544 | 2024-10-21 | Warnings | 362O9ITL9D |
| Mucus Relief Cold and Flu | ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | HEB | b1ba8ade-3441-f243-e053-2995a90a1230 | 2024-10-21 | Warnings | 362O9ITL9D |
| Mucus Relief Cold, Flu and Sore Throat | ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | HEB | b1ba22ac-c38d-a42e-e053-2995a90a6900 | 2024-10-21 | Warnings | 362O9ITL9D |
| Acetaminophen Extra Strength | ACETAMINOPHEN | KROGER COMPANY | cf63c372-acdd-6e6e-e053-2995a90a1662 | 2024-10-21 | Warnings | M013 362O9ITL9D |
| good sense pain relief | ACETAMINOPHEN | L. Perrigo Company | 8b56bfc0-2253-458d-99a6-0b0f9ae0ba50 | 2024-10-21 | Warnings | M013 313782 362O9ITL9D |
| Acetaminophen | ACETAMINOPHEN | KROGER COMPANY | b9b63c38-83e7-62d2-e053-2a95a90a5526 | 2024-10-19 | Warnings | 362O9ITL9D |
| Aspirin | ASPIRIN | GOODSENSE | 662a2bc6-9507-465c-b467-7ae1b2e1dedc | 2024-10-18 | Warnings | M013 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.